Tapewire

Nasdaq · USD

BDTX

Black Diamond Therapeutics, Inc.

Export transactions ↓
Tapewire entity
6669
SEC CIK
0001701541
Parsed reports
283

Last 12 months

Inside the activity.

0 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 18, 2026 Filed Sep 21, 2026 21:45 UTC GrantCommon Stock 7,707 $1.93 $14,874.51
Disclosure

SEC source: 0001193125-26-396868 · ownership.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,236

F1 · kind: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026.

Read SEC document
September 18, 2026 Filed Sep 21, 2026 21:30 UTC GrantCommon Stock 6,801 $1.93 $13,125.93
Disclosure

SEC source: 0002018686-26-000014 · form4-09212026_090921.xml · nonDerivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,840

F1 · kind: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 20:40 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001193125-26-288598 · ownership.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 20:37 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001682019-26-000002 · form4-06292026_080654.xml · derivative · entry 1

Kulkarni Samarth · CIK 0001682019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 20:36 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0002018686-26-000012 · form4-06292026_080611.xml · derivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 20:37 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001556064-26-000002 · form4-06292026_080611.xml · derivative · entry 1

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 20:34 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001456849-26-000002 · form4-06292026_080659.xml · derivative · entry 1

Dhingra Kapil · CIK 0001456849 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 20:32 UTC GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0002018966-26-000007 · form4-06292026_080653.xml · derivative · entry 1

Campbell Shannon · CIK 0002018966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-06-25

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 19, 2026 Filed Jun 22, 2026 20:19 UTC GrantCommon Stock 8,961 $1.66 $14,875.26
Disclosure

SEC source: 0001193125-26-277553 · ownership.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,529

F1 · kind: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026.

Read SEC document
June 19, 2026 Filed Jun 22, 2026 20:06 UTC GrantCommon Stock 7,907 $1.66 $13,125.62
Disclosure

SEC source: 0002018686-26-000008 · form4-06222026_080600.xml · nonDerivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,039

F1 · kind: These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026.

Read SEC document
March 20, 2026 Filed Mar 20, 2026 21:27 UTC GrantCommon Stock 6,919 $2.15 $14,875.85
Disclosure

SEC source: 0001193125-26-117938 · ownership.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,568

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026.

Read SEC document
March 20, 2026 Filed Mar 20, 2026 21:19 UTC GrantCommon Stock 6,105 $2.15 $13,125.75
Disclosure

SEC source: 0002018686-26-000002 · form4-03202026_090300.xml · nonDerivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,132

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026.

Read SEC document
January 21, 2026 Filed Jan 23, 2026 16:05 UTC
Jones ErikaSEE REMARKS
GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $2.57 $0.00
Disclosure

SEC source: 0001895913-26-000002 · form4-01232026_040111.xml · derivative · entry 1

Jones Erika · CIK 0001895913 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2036-01-20

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 21, 2026 Filed Jan 23, 2026 16:05 UTC
Buck ElizabethCHIEF SCIENTIFIC OFFICER
GrantStock Option (Right to Buy) · Derivative 250,000 $0.00 Strike: $2.57 $0.00
Disclosure

SEC source: 0001880385-26-000002 · form4-01232026_040106.xml · derivative · entry 1

Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-01-20

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 21, 2026 Filed Jan 23, 2026 21:05 UTC GrantStock Option (Right to Buy) · Derivative 250,000 $0.00 Strike: $2.57 $0.00
Disclosure

SEC source: 0001637054-26-000002 · form4-01232026_040109.xml · derivative · entry 1

Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-01-20

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 21, 2026 Filed Jan 23, 2026 21:05 UTC
Yurasov SergeyCHIEF MEDICAL OFFICER
GrantStock Option (Right to Buy) · Derivative 250,000 $0.00 Strike: $2.57 $0.00
Disclosure

SEC source: 0001686295-26-000002 · form4-01232026_040104.xml · derivative · entry 1

Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2036-01-20

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 21, 2026 Filed Jan 23, 2026 21:05 UTC
Velleca Mark A.Director · PRESIDENT & CEO
GrantStock Option (Right to Buy) · Derivative 600,000 $0.00 Strike: $2.57 $0.00
Disclosure

SEC source: 0001706847-26-000002 · form4-01232026_040101.xml · derivative · entry 1

Velleca Mark A. · CIK 0001706847 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2036-01-20

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
December 12, 2025 Filed Dec 15, 2025 21:39 UTC GrantCommon Stock 5,208 $2.76 $14,374.08
Disclosure

SEC source: 0001193125-25-319303 · ownership.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,649

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025.

Read SEC document
December 12, 2025 Filed Dec 15, 2025 21:33 UTC GrantCommon Stock 4,665 $2.76 $12,875.40
Disclosure

SEC source: 0002018686-25-000007 · form4-12152025_091210.xml · nonDerivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,027

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025.

Read SEC document
September 19, 2025 Filed Sep 22, 2025 21:45 UTC GrantCommon Stock 3,843 $3.35 $12,874.05
Disclosure

SEC source: 0002018686-25-000004 · form4-09222025_090933.xml · nonDerivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,362

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 18, 2025.

Read SEC document
September 19, 2025 Filed Sep 22, 2025 21:58 UTC GrantCommon Stock 4,291 $3.35 $14,374.85
Disclosure

SEC source: 0001193125-25-211678 · ownership.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,441

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 18, 2025.

Read SEC document
June 20, 2025 Filed Jun 20, 2025 20:21 UTC GrantCommon Stock 6,170 $2.33 $14,376.10
Disclosure

SEC source: 0000950170-25-088527 · ownership.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,150

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025.

Read SEC document
June 20, 2025 Filed Jun 20, 2025 20:12 UTC GrantCommon Stock 5,526 $2.33 $12,875.58
Disclosure

SEC source: 0001415889-25-017821 · form4-06202025_080647.xml · nonDerivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,519

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025.

Read SEC document
June 12, 2025 Filed Jun 12, 2025 22:34 UTC GrantStock Option (Right to Buy) · Derivative 30,550 $0.00 Strike: $2.43 $0.00
Disclosure

SEC source: 0000950170-25-085676 · ownership.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,550

Underlying: Common Stock · 30,550 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 12, 2025 Filed Jun 12, 2025 22:26 UTC GrantStock Option (Right to Buy) · Derivative 30,550 $0.00 Strike: $2.43 $0.00
Disclosure

SEC source: 0001415889-25-017058 · form4-06122025_100637.xml · derivative · entry 1

Menzel Garry E · CIK 0001556064 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,550

Underlying: Common Stock · 30,550 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 12, 2025 Filed Jun 12, 2025 22:25 UTC GrantStock Option (Right to Buy) · Derivative 30,550 $0.00 Strike: $2.43 $0.00
Disclosure

SEC source: 0001415889-25-017056 · form4-06122025_100652.xml · derivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,550

Underlying: Common Stock · 30,550 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 12, 2025 Filed Jun 12, 2025 22:24 UTC GrantStock Option (Right to Buy) · Derivative 30,550 $0.00 Strike: $2.43 $0.00
Disclosure

SEC source: 0001415889-25-017053 · form4-06122025_100629.xml · derivative · entry 1

Campbell Shannon · CIK 0002018966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,550

Underlying: Common Stock · 30,550 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 12, 2025 Filed Jun 12, 2025 22:23 UTC GrantStock Option (Right to Buy) · Derivative 30,550 $0.00 Strike: $2.43 $0.00
Disclosure

SEC source: 0001415889-25-017050 · form4-06122025_100609.xml · derivative · entry 1

Dhingra Kapil · CIK 0001456849 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,550

Underlying: Common Stock · 30,550 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
June 12, 2025 Filed Jun 12, 2025 22:22 UTC GrantStock Option (Right to Buy) · Derivative 30,550 $0.00 Strike: $2.43 $0.00
Disclosure

SEC source: 0001415889-25-017048 · form4-06122025_100615.xml · derivative · entry 1

Kulkarni Samarth · CIK 0001682019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,550

Underlying: Common Stock · 30,550 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Read SEC document
March 21, 2025 Filed Mar 21, 2025 20:19 UTC GrantCommon Stock 7,646 $1.88 $14,374.48
Disclosure

SEC source: 0000950170-25-043221 · ownership.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,980

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 20, 2025.

Read SEC document
March 21, 2025 Filed Mar 21, 2025 20:04 UTC GrantCommon Stock 6,848 $1.88 $12,874.24
Disclosure

SEC source: 0001415889-25-008771 · form4-03212025_080359.xml · nonDerivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,993

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 20, 2025.

Read SEC document
March 19, 2025 Filed Mar 21, 2025 01:01 UTC
BB BIOTECH AG10% owner
SaleCommon Stock 500,000 $2.12 $1,058,450.00
Disclosure

SEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 7

BIOTECH GROWTH N V · CIK 0001259869 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,733,547

Read SEC document
March 19, 2025 Filed Mar 21, 2025 01:01 UTC
BB BIOTECH AG10% owner
SaleCommon Stock 584,292 $1.95 $1,141,239.13
Disclosure

SEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 6

BIOTECH GROWTH N V · CIK 0001259869 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,233,547

Read SEC document
March 19, 2025 Filed Mar 21, 2025 01:01 UTC
BB BIOTECH AG10% owner
SaleCommon Stock 400,000 $2.09 $837,160.00
Disclosure

SEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 5

BIOTECH GROWTH N V · CIK 0001259869 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,817,839

Read SEC document
March 19, 2025 Filed Mar 21, 2025 01:01 UTC
BB BIOTECH AG10% owner
SaleCommon Stock 2,000,000 $2.00 $4,000,800.00
Disclosure

SEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 4

BIOTECH GROWTH N V · CIK 0001259869 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,217,839

Read SEC document
March 19, 2025 Filed Mar 21, 2025 01:01 UTC
BB BIOTECH AG10% owner
SaleCommon Stock 1,000,000 $2.31 $2,308,100.00
Disclosure

SEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 3

BIOTECH GROWTH N V · CIK 0001259869 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,217,839

Read SEC document
March 19, 2025 Filed Mar 21, 2025 01:01 UTC
BB BIOTECH AG10% owner
SaleCommon Stock 300,000 $1.94 $582,900.00
Disclosure

SEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 2

BIOTECH GROWTH N V · CIK 0001259869 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,217,839

Read SEC document
March 19, 2025 Filed Mar 21, 2025 01:01 UTC
BB BIOTECH AG10% owner
SaleCommon Stock 1,000,000 $2.07 $2,069,100.00
Disclosure

SEC source: 0001104659-25-026305 · tm259930-1_4seq1.xml · nonDerivative · entry 1

BIOTECH GROWTH N V · CIK 0001259869 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,517,839

Read SEC document
January 30, 2025 Filed Jan 31, 2025 16:35 UTC
Jones ErikaSEE REMARKS
GrantStock Option (Right to Buy) · Derivative 125,000 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001415889-25-002489 · form4-01312025_090143.xml · derivative · entry 2

Jones Erika · CIK 0001895913 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2035-01-29

F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 16:35 UTC
Jones ErikaSEE REMARKS
GrantCommon Stock 75,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-002489 · form4-01312025_090143.xml · nonDerivative · entry 1

Jones Erika · CIK 0001895913 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,150

F1 · kind: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 16:36 UTC
Buck ElizabethCHIEF SCIENTIFIC OFFICER
GrantStock Option (Right to Buy) · Derivative 175,000 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001415889-25-002492 · form4-01312025_090123.xml · derivative · entry 2

Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2035-01-29

F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 16:36 UTC
Buck ElizabethCHIEF SCIENTIFIC OFFICER
GrantCommon Stock 75,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-002492 · form4-01312025_090123.xml · nonDerivative · entry 1

Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,192

F1 · kind: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:37 UTC
Velleca Mark A.Director · PRESIDENT & CEO
GrantStock Option (Right to Buy) · Derivative 500,000 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001415889-25-002494 · form4-01312025_090114.xml · derivative · entry 2

Velleca Mark A. · CIK 0001706847 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2035-01-29

F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:37 UTC
Velleca Mark A.Director · PRESIDENT & CEO
GrantCommon Stock 75,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-002494 · form4-01312025_090114.xml · nonDerivative · entry 1

Velleca Mark A. · CIK 0001706847 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,522

F1 · kind: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:36 UTC
Yurasov SergeyCHIEF MEDICAL OFFICER
GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001415889-25-002493 · form4-01312025_090152.xml · derivative · entry 2

Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-01-29

F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:36 UTC
Yurasov SergeyCHIEF MEDICAL OFFICER
GrantCommon Stock 75,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-002493 · form4-01312025_090152.xml · nonDerivative · entry 1

Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

F1 · kind: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:35 UTC GrantStock Option (Right to Buy) · Derivative 175,000 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001415889-25-002486 · form4-01312025_090101.xml · derivative · entry 2

Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2035-01-29

F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:35 UTC GrantCommon Stock 75,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-002486 · form4-01312025_090101.xml · nonDerivative · entry 1

Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,400

F1 · kind: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
December 13, 2024 Filed Dec 16, 2024 22:09 UTC GrantCommon Stock 5,750 $2.50 $14,375.00
Disclosure

SEC source: 0000950170-24-136739 · ownership.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,334

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024.

Read SEC document
December 13, 2024 Filed Dec 16, 2024 21:34 UTC GrantCommon Stock 5,150 $2.50 $12,875.00
Disclosure

SEC source: 0001415889-24-029482 · form4-12162024_091237.xml · nonDerivative · entry 1

Raman Prakash · CIK 0002018686 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,145

F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.